Jiangsu T-Mab Biopharma Co.,Ltd   Report issue

For profit Phase 1
Founded: Jiangsu China (2012)

Organization Overview

First Clinical Trial
2013
NCT02156388
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Jiangsu T-Mab Biopharma Co.,Ltd

Active Ingredients

Drugs in Phase 1 Trials (4)

denosumab (prolia) (3 trials)

Filgrastim (neupogen) (1 trial)

gw003 (3 trials)

tk001 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 1)

Macular Degeneration (Phase 1)

Neoplasm Metastasis (Phase 1)

Neutropenia (Phase 1)

Osteoporosis (Phase 1)

Wet Macular Degeneration (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 8
  • # of Trial APIs: 4